

TERIS Summary

TERIS Agent Number: 6872
Agent Name: **REGDANVIMAB**

Bibliographic Search Date: 09/2022

Regdanvimab is a human monoclonal antibody that targets the SARS-CoV-2 spike protein. Regdanvimab is administered intravenously for the treatment of COVID-19.

Magnitude of Teratogenic Risk to Child Born After Exposure During Gestation: UNDETERMINED

Quality and Quantity of Data on Which Risk Estimate is Based: NONE

Comments: BECAUSE REGDANVIMAB IS AN ANTIBODY, IT MAY BE ACTIVELY TRANSPORTED ACROSS THE PLACENTA IN LATER PREGNANCY.

Summary of Teratology Studies:

MAJOR CONGENITAL ANOMALIES

No epidemiological studies of congenital anomalies among infants born to women who were treated with regdanvimab during pregnancy have been reported.

ANIMAL TERATOLOGY STUDIES

Animal teratology studies of regdanvimab conducted by the manufacturer have not been published in the peer-reviewed literature.

Selected References:

(Each paper is classified as a review [R], human case report [C], human epidemiological study [E], human clinical series [S], animal study [A], or other [O].)

None available.